CALQUENCE has been used to treat more than 85,000 patients worldwide 9 and is approved for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma ...

Covid-19 patients who were on supplemental oxygen did better with Calquence than those on ventilators, the study showed. After being treated with Calquence for 10 to 14 days, 9 out of 11, or 82% ...

Calquence, which was approved in the U.S. for chronic lymphocytic leukemia patients in November, was the only product of Acerta, which was acquired by AstraZeneca in a $7 billion deal in 2016.

I’m in remission from small lymphocytic lymphoma and off treatment, savoring this break while learning to live with the ...

CALQUENCE reduced the risk of disease progression or death by 71% vs. standard of care combinations at three years in the ASCEND Phase III trial ...

Positive high-level results from an interim analysis of the AMPLIFY Phase III trial showed a fixed duration of AstraZeneca’ s CALQUENCE ® in combination with venetoclax, with or without ...

At 12 months, 88% of patients on CALQUENCE showed no disease progression compared to 68% for the control arm. The safety and tolerability of CALQUENCE was consistent with its established profile.

Updated results from the ASCEND Phase III trial showed AstraZeneca’ s CALQUENCE ® maintained a statistically significant progression-free survival benefit at three years compared to ...

The distribution of these baseline cardiovascular disorders was also comparable between the Calquence and comparator arms across the various studies. Specifically, 599 patients received Calquence ...

AstraZeneca shares data from the ECHO Phase 3 trial on Calquence plus bendamustine and rituximab in untreated mantle cell lymphoma patients over 65.

WILMINGTON, Del., January 17, 2025--AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with ...

Positive high-level results from an interim analysis of the AMPLIFY Phase III trial showed a fixed duration of AstraZeneca’s CALQUENCE ® (acalabrutinib) in combination with venetoclax, with or ...